Capricor Therapeutics, Inc. (CAPR) Stock Analysis and Metrics

Capricor Therapeutics

NASDAQ: CAPR

$19.70 ▼ -0.13 (-0.66%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.12 Bn

P/E-5.23

Div. Yield0.00

Add ratio to table…

About

Capricor Therapeutics Inc is a biotechnology company focused on the development and potential commercialization of cell and exosome based therapeutics for the treatment of Duchenne muscular dystrophy and other diseases with significant unmet medical need.

Capricor Therapeutics Inc generates revenue primarily through collaboration agreements milestone payments upfront fees and government grants. The company has received upfront and milestone payments from its distribution partner Nippon Shinyaku Co Ltd for Deramiocel and also receives funding from the National Institutes of Health and other agencies for its exosome based vaccine and therapeutic programs. Currently the company has no products approved for commercial sale so future revenue will depend on regulatory approval and sales of its product candidates.

Capricor Therapeutics Inc occupies a niche in the biotechnology sector focusing on cell therapy and exosome platform technologies for rare muscle diseases. Its lead candidate Deramiocel competes with exon skipping therapies such as Sarepta Therapeutics eteplirsen casimersen golodirsen and viltolarsen and with gene therapy approaches like Sarepta delandistrogene moxeparvovec. Competitive advantages include Deramiocel's mechanism targeting inflammation and fibrosis its orphan drug rare pediatric disease and RMAT designations and its partnerships with Nippon Shinyaku and the National Institutes of Health which provide development resources and potential commercialization pathways.

The company serves patients with Duchenne muscular dystrophy Becker muscular dystrophy and individuals at risk of infectious diseases such as SARS CoV 2. Its collaboration network includes Nippon Shinyaku Co Ltd as exclusive distributor in the United States and Japan the National Institute of Allergy and Infectious Diseases for its exosome based vaccine research and various academic institutions such as Johns Hopkins University and Cedars Sinai Medical Center for technology licensing and research support.

Investment Thesis

▲ Bull case

Capricor’s deramiocel is positioned to secure FDA approval with a PDUFA date of August 22, 2026, supported by robust HOPE-3 trial data showing a 54% reduction in upper limb disease severity (p=0.029) and a 91% slowing of cardiomyopathy progression in left ventricular ejection fraction (LVEF), with a subset of cardiomyopathy patients demonstrating a 120% slowing of disease progression (p=0.01). These clinically meaningful endpoints, validated across multiple peer-reviewed presentations at MDA, AAN, and ASCGT conferences, provide a strong foundation for labeling discussions that could support early treatment initiation and broader patient access. The FDA’s classification of the resubmission as a Class 2 response, coupled with the company’s ability to address all information requests, indicates a review process progressing without major hurdles, increasing confidence in approval timing. The lawsuit against NS Pharma, while perceived as a near-term risk, presents a strategic opportunity to regain full commercial control of deramiocel, eliminating a structurally flawed distribution agreement that would have imposed hundreds of thousands of dollars in reimbursement shortfalls per dose for Medicare, Medicaid, and private insurance patients. Capricor has proactively built commercial readiness independently, securing a Chief Commercial Officer with rare disease experience, identifying a 3PL distributor, and advancing patient support infrastructure—all while maintaining open-label extension patient access to therapy. This positions the company to launch immediately post-approval without dependency on a partner unwilling to fix commercial terms, ensuring patient access is not delayed by contractual dysfunction. Capricor’s in-house GMP manufacturing facility in San Diego has successfully completed its FDA pre-license inspection, with current capacity for 200–250 patients annually (1,000 doses) and an ongoing expansion to support 2,000–2,500 patients per year (10,000 doses) by 2027. The facility’s readiness to stockpile commercial doses under an interim label solution—acknowledged and supported by the FDA—eliminates a critical bottleneck for ultra-cold chain products. Combined with a strong balance sheet of $279 million in cash and equivalents as of March 31, 2026, Capricor has sufficient runway to fund operations into 2027 without dilution, enabling execution of commercialization, manufacturing scale-up, and pipeline expansion efforts post-approval. Beyond deramiocel, Capricor’s pipeline expansion into Becker Muscular Dystrophy (BMD) represents a significant near-term catalyst, with a U.S. patient population of approximately 5,000 annually and identical pathophysiology to DMD. The company plans to engage the FDA immediately post-PDUFA for DMD to initiate clinical pathways for BMD, leveraging its priority review voucher (PRV) eligibility—which requires exclusive pediatric indication focus—to secure non-dilutive capital through PRV monetization. This sequential strategy allows Capricor to de-risk its DMD launch while positioning for rapid expansion into BMD, avoiding dilution and creating a multi-indication franchise from a single therapeutic platform.

Capricor’s deramiocel is positioned to secure FDA approval with a PDUFA date of August 22, 2026, supported by robust HOPE-3 trial data showing a 54% reduction in upper limb disease severity (p=0.029) and a 91% slowing of cardiomyopathy progression in left ventricular ejection fraction (LVEF), with a subset of cardiomyopathy patients demonstrating a 120% slowing of disease progression (p=0.01). These clinically meaningful endpoints, validated across multiple peer-reviewed presentations at MDA, AAN, and ASCGT conferences, provide a strong foundation for labeling discussions that could support early treatment initiation and broader patient access. The FDA’s classification of the resubmission as a Class 2 response, coupled with the company’s ability to address all information requests, indicates a review process progressing without major hurdles, increasing confidence in approval timing. The lawsuit against NS Pharma, while perceived as a near-term risk, presents a strategic opportunity to regain full commercial control of deramiocel, eliminating a structurally flawed distribution agreement that would have imposed hundreds of thousands of dollars in reimbursement shortfalls per dose for Medicare, Medicaid, and private insurance patients. Capricor has proactively built commercial readiness independently, securing a Chief Commercial Officer with rare disease experience, identifying a 3PL distributor, and advancing patient support infrastructure—all while maintaining open-label extension patient access to therapy. This positions the company to launch immediately post-approval without dependency on a partner unwilling to fix commercial terms, ensuring patient access is not delayed by contractual dysfunction. Capricor’s in-house GMP manufacturing facility in San Diego has successfully completed its FDA pre-license inspection, with current capacity for 200–250 patients annually (1,000 doses) and an ongoing expansion to support 2,000–2,500 patients per year (10,000 doses) by 2027. The facility’s readiness to stockpile commercial doses under an interim label solution—acknowledged and supported by the FDA—eliminates a critical bottleneck for ultra-cold chain products. Combined with a strong balance sheet of $279 million in cash and equivalents as of March 31, 2026, Capricor has sufficient runway to fund operations into 2027 without dilution, enabling execution of commercialization, manufacturing scale-up, and pipeline expansion efforts post-approval. Beyond deramiocel, Capricor’s pipeline expansion into Becker Muscular Dystrophy (BMD) represents a significant near-term catalyst, with a U.S. patient population of approximately 5,000 annually and identical pathophysiology to DMD. The company plans to engage the FDA immediately post-PDUFA for DMD to initiate clinical pathways for BMD, leveraging its priority review voucher (PRV) eligibility—which requires exclusive pediatric indication focus—to secure non-dilutive capital through PRV monetization. This sequential strategy allows Capricor to de-risk its DMD launch while positioning for rapid expansion into BMD, avoiding dilution and creating a multi-indication franchise from a single therapeutic platform.

▼ Bear case

Capricor’s reliance on the FDA’s approval of deramiocel by August 22, 2026, remains highly uncertain despite positive HOPE-3 data, as the agency’s Class 2 resubmission classification does not guarantee approval and the company has not disclosed specific feedback on labeling discussions or potential clinical hold risks. The absence of revenue in Q1 2026 and Q1 2025, coupled with rising operating expenses ($36.8 million vs. $25 million year-over-year), reflects a cash burn trajectory that assumes approval and commercialization will occur on schedule—any delay in FDA action beyond the PDUFA date would rapidly erode the $279 million cash buffer, potentially necessitating dilutive financing before revenue materializes. The lawsuit against NS Pharma introduces significant execution risk, as Capricor’s assumption of securing a quick preliminary injunction and immediate post-approval launch overlooks potential procedural delays, appeals, or unfavorable rulings that could extend litigation well beyond the PDUFA date. Even if the injunction is granted, the company’s commercial readiness claims—such as having a 3PL distributor identified and a Chief Commercial Officer hired—remain unvalidated in practice, with no disclosed timelines for finalizing contracts, training sales teams, or establishing payer contracts, leaving a material gap between preparedness and actual launch capability. Capricor’s manufacturing expansion plans, targeting 2,000–2,500 patients annually by 2027, are contingent on successful FDA validation of the second-floor clean rooms, a process with no guaranteed timeline and inherent technical risks in scaling ultra-cold chain biologics production. The company’s current capacity of 200–250 patients annually (1,000 doses) is insufficient to meet even modest post-launch demand, and any delays in expansion—common in biomanufacturing—would create a supply bottleneck that could trigger payer restrictions, physician hesitancy, or black-market diversion, undermining commercial uptake despite approval. The pivot to Becker Muscular Dystrophy as a near-term pipeline catalyst is speculative and premature, as Capricor has not initiated any preclinical or clinical work specific to BMD beyond pathophysiological rationale, and the FDA’s requirement for PRV eligibility (exclusive pediatric indication focus) may be challenged if BMD development is perceived as diluting the pediatric focus of deramiocel for DMD. Furthermore, the BMD market of 5,000 U.S. patients is ultra-niche, and achieving reimbursement or physician adoption in this population would require identical commercial infrastructure investments as DMD—yet Capricor has disclosed zero biomarkers, endpoints, or trial designs for BMD, making this expansion a high-risk, low-probability diversion of scarce resources from the core DMD launch effort.

Capricor’s reliance on the FDA’s approval of deramiocel by August 22, 2026, remains highly uncertain despite positive HOPE-3 data, as the agency’s Class 2 resubmission classification does not guarantee approval and the company has not disclosed specific feedback on labeling discussions or potential clinical hold risks. The absence of revenue in Q1 2026 and Q1 2025, coupled with rising operating expenses ($36.8 million vs. $25 million year-over-year), reflects a cash burn trajectory that assumes approval and commercialization will occur on schedule—any delay in FDA action beyond the PDUFA date would rapidly erode the $279 million cash buffer, potentially necessitating dilutive financing before revenue materializes. The lawsuit against NS Pharma introduces significant execution risk, as Capricor’s assumption of securing a quick preliminary injunction and immediate post-approval launch overlooks potential procedural delays, appeals, or unfavorable rulings that could extend litigation well beyond the PDUFA date. Even if the injunction is granted, the company’s commercial readiness claims—such as having a 3PL distributor identified and a Chief Commercial Officer hired—remain unvalidated in practice, with no disclosed timelines for finalizing contracts, training sales teams, or establishing payer contracts, leaving a material gap between preparedness and actual launch capability. Capricor’s manufacturing expansion plans, targeting 2,000–2,500 patients annually by 2027, are contingent on successful FDA validation of the second-floor clean rooms, a process with no guaranteed timeline and inherent technical risks in scaling ultra-cold chain biologics production. The company’s current capacity of 200–250 patients annually (1,000 doses) is insufficient to meet even modest post-launch demand, and any delays in expansion—common in biomanufacturing—would create a supply bottleneck that could trigger payer restrictions, physician hesitancy, or black-market diversion, undermining commercial uptake despite approval. The pivot to Becker Muscular Dystrophy as a near-term pipeline catalyst is speculative and premature, as Capricor has not initiated any preclinical or clinical work specific to BMD beyond pathophysiological rationale, and the FDA’s requirement for PRV eligibility (exclusive pediatric indication focus) may be challenged if BMD development is perceived as diluting the pediatric focus of deramiocel for DMD. Furthermore, the BMD market of 5,000 U.S. patients is ultra-niche, and achieving reimbursement or physician adoption in this population would require identical commercial infrastructure investments as DMD—yet Capricor has disclosed zero biomarkers, endpoints, or trial designs for BMD, making this expansion a high-risk, low-probability diversion of scarce resources from the core DMD launch effort.

Type of Arrangement and Non-arrangement Transactions Breakdown of Revenue (2024)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2024)

Type of Arrangement and Non-arrangement Transactions Breakdown of Revenue (2024)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2024)

Type of Arrangement and Non-arrangement Transactions Breakdown of Revenue (2024)

Peer Comparison

Create an account

Sign In

Reset Password